A Look At ACADIA Pharmaceuticals (ACAD) Valuation After A 29.11% One Year Total Return

NodeGuardian · 2026-03-05T14:51:06+00:00

ACADIA Pharmaceuticals has generated a 29.11% return in the past year, with shares undervalued by 20%. The company plans to expand its pipeline, with several late-stage programs expected by 2027, presenting growth opportunities alongside existing product risks.

NodeGuardian

2026-03-05 14:51:06

Abstract generation in progress

ACADIA Pharmaceuticals (ACAD) has seen a 29.11% total return over the past year, with its share price at US$24.97 suggesting it is undervalued by approximately 20% compared to a fair value of $31.21. The company’s pipeline includes nine programs, with multiple late-stage clinical readouts expected by 2027, aiming to diversify revenue beyond NUPLAZID. Investors are encouraged to assess the risks and rewards, considering both the potential for growth and the reliance on its current main product.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.